Perioperative insulin therapy using a closed-loop artificial endocrine pancreas after hepatic resection

Takehiro Okabayashi, Hiromichi Maeda, Zhao-Li Sun, Robert A Montgomery, Isao Nishimori, Kazuhiro Hanazaki

Abstract
Postoperative hyperglycemia is common in critically ill patients, even in those without a prior history of diabetes mellitus. It is well known that hyperglycemia induced by surgical stress often results in dysregulation of liver metabolism and immune function, impairing postoperative recovery. Current evidence suggests that maintaining normoglycemia postoperatively improves surgical outcome and reduces the mortality and morbidity of critically ill patients. On the basis of these observations, several large randomized controlled studies were designed to evaluate the benefit of postoperative tight glycemic control with intensive insulin therapy. However, intensive insulin therapy carries the risk of hypoglycemia, which is linked to serious neurological events. Recently, we demonstrated that perioperative tight glycemic control in surgical patients could be achieved safely using a closed-loop glycemic control system and that this decreased both the incidence of infection at the site of the surgical incision, without the appearance of hypoglycemia, and actual hospital costs. Here, we review the benefits and requirements of perioperative intensive insulin therapy using a closed-loop artificial endocrine pancreas system in hepatsectomized patients. This novel intensive insulin therapy is safe and effectively improves surgical outcome after hepatic resection.
Hyperglycemia has a deleterious effect on cells that passively take up glucose independent of insulin, including hepatocytes, alveolar cells, endothelial cells, neurons, and immune cells. Postoperative hyperglycemia is common in critically ill patients, even in those without a prior history of diabetes mellitus. It is well known that hyperglycemia induced by surgical stress often results in dysregulation of liver metabolism and immune function, leading to impaired postoperative recovery. Thus, the prevention of glucose toxicity in the mitochondrial compartment is important.

In this Topic Highlight, we review the benefits and requirements of tight glycemic control in hepatic surgery, with a focus on postoperative infection control. We suggest that perioperative intensive insulin therapy using a closed-loop artificial endocrine pancreas system is safe and effectively improves surgical outcome after hepatic resection.

CURRENT STATE OF TIGHT GLYCEMIC CONTROL IN CRITICALLY ILL PATIENTS

In large randomized trials in which the use of tight blood glucose control (80-110 mg/dL) with intensive insulin therapy was compared with standard blood glucose control (<200 mg/dL) in surgical intensive care unit (ICU) patients, strict control of postoperative blood glucose levels was shown to significantly reduce patient mortality and morbidity. In addition, postoperative hyperglycemia has been shown to be associated with an increased risk of surgical site infection (SSI). Current evidence suggests that maintaining normoglycemia postoperatively improves surgical outcome and reduces mortality and morbidity in critically ill patients. These observations led to several short-lived multicenter randomized controlled studies designed to evaluate the benefit of tight glycemic control with intensive insulin therapy. The main reason for the early cessation of these clinical trials was the high incidence of hypoglycemia (10%-17%) induced by the intensive insulin therapy, which could not be prevented because of technical limitations at that time. However, the subsequent development of accurate continuous blood glucose monitoring devices and closed-loop systems for computer-assisted blood glucose control in the ICU will likely reduce the incidence of hypoglycemia in these situations.

For the reasons described above, achieving tight glycemic control with intensive insulin therapy has come under increased scrutiny in the management of patients in the surgical ICU. Recently, we demonstrated in two retrospective studies and in one randomized clinical trial that perioperative tight glycemic control using a closed-loop glycemic control system for patients undergoing liver resection was safe and effective in decreasing the incidence of SSI without increasing the risk of hypoglycemia.

INSULIN THERAPY IN THE SURGICAL ICU

In all three studies, perioperative blood glucose concentrations were monitored continuously using the STG-22 system, developed by Nikkiso Co. (Tokyo, Japan). Patients were divided into two groups: one in which glucose levels were controlled by manual injection of insulin according to the commonly used sliding-scale method (SS group) and a second group in which programmed infusions of insulin were administered as determined by the control algorithm of a closed-loop artificial endocrine system (AP group).

Conventional insulin therapy using the sliding-scale method

Blood glucose levels in patients in the SS group were monitored continuously by the artificial pancreas and patients were checked routinely by nursing staff every 2 h. Blood glucose levels in these patients were controlled by subcutaneous injections of regular human insulin, with the dose determined by the sliding-scale method and the target blood glucose level to avoid hypoglycemia set at 150-200 mg/dL.

Novel insulin therapy using a closed-loop artificial endocrine pancreas system

The STG-22 unit was developed in 1984 by Nikkiso Co. as a closed-loop artificial endocrine pancreas system. The STG-22 system is a reliable and accurate device that measures blood glucose concentrations continuously and is comparable to the ABL 800FLEX machine (Radiometer Medical Aps, Bronshoj, Denmark) recommended by the National Committee for Clinical Laboratory Standards. The STG-22 closed-loop glycemic control system is composed of a glucose sensor for the detection and/or monitoring of glucose and pumps for the infusion of appropriate amounts of insulin or glucose. The insulin and glucose pumps are regulated by a computer on the basis of target blood glucose values that are defined prior to initiation of the system. The STG-22 maintains stable blood glucose concentrations by automatic infusion of regular insulin or glucose into the circulation. In the ICU, peripheral blood was sampled continuously at 2 mL/h over the first 18 h postoperatively to monitor glucose levels. In addition, the STG-22 was used to evaluate the patients’ insulin requirements.

Statistical analysis

Continuous variables are presented as the mean ± SD. Dichotomous variables are presented as both absolute numbers and percentages. Data were analyzed using Student’s t-test (two-tailed), with dichotomous variables analyzed by the χ2 test (two-tailed) or Fisher’s exact test (two-tailed). P < 0.05 was considered significant. All analyses were performed using SPSS software (SPSS, Chicago, IL, USA).
RETROSPECTIVE STUDIES

The benefits of using a closed-loop glycemic control system in patients after hepatectomy were investigated in two retrospective studies. The aim of the first study was to evaluate the usefulness of the closed-loop system in providing continuous monitoring and strict control of postoperative blood glucose levels in patients after hepatic resection[25]. The aim of the second study was to identify, using multivariate analysis, risk factors and predictors of SSI, as well as how to prevent the development of SSI, in a consecutive series of patients undergoing hepatic resection for liver disease in a single institution.

In the first study[25], postoperative blood glucose levels increased initially in the SS group, reaching a plateau of approximately 250 mg/dL between 4 and 7 h after hepatectomy. Thereafter, blood glucose levels decreased, returning to normal within 16 h after surgery. In the AP group, blood glucose decreased gradually, reaching target levels (90-110 mg/dL) within 12 h after surgery. Total insulin administered per patient during the first 16 h after surgery was significantly higher in the AP group compared with the SS group (183 ± 188 IU vs 8 ± 7 IU, respectively, P < 0.001). These data suggest that the sliding-scale method is not as effective as the closed-loop artificial endocrine system in preventing hyperglycemia resulting from disturbed glucose metabolism following liver resection.

In the second study[26], the association between SSI and various clinical parameters was investigated in 152 patients following hepatic resection. The incidence of SSI in these patients was 14.5%. Multivariate analysis identified four independent parameters that were correlated with the occurrence of SSI, namely (1) body mass index > 23.6 kg/m², (2) estimated blood loss volume > 810 mL, (3) the presence of postoperative bile leak organ/space SSI; and (4) use of the sliding-scale method for postoperative glucose control. No SSI was observed after liver resection in patients in whom postoperative blood glucose levels were controlled by an artificial pancreas. The results of this second retrospective study demonstrated that a lack of postoperative glycemic control is associated with a significantly higher incidence of postoperative infectious complications and a longer period of hospitalization.

PROSPECTIVE RANDOMIZED CLINICAL TRIAL

A prospective randomized trial was conducted in patients undergoing hepatic resection to evaluate the postoperative condition of the patients and the effects of a closed-loop artificial pancreas on tight glycemic control during intensive insulin therapy after hepatectomy[27]. Patients were randomly assigned to receive intensive insulin therapy using a closed-loop glycemic control system (i.e. an artificial pancreas; target blood glucose 80-110 mg/dL; AP group) or conventional insulin therapy using the sliding-scale method (target blood glucose 150-200 mg/dL; SS group). Perioperative blood glucose levels were monitored continuously in both groups using a closed-loop system. Neither group experienced hypoglycemia (blood glucose < 40 mg/dL). Although perioperative blood glucose levels in the AP group were close to 100 mg/dL, those in the SS group were > 150 mg/dL, which is the same as in our first retrospective study[26] (Figure 1). The incidence of SSI was significantly lower in the AP than in the SS group (2.3% vs 18.2%, respectively, P = 0.030), the duration of hospitalization was significantly shorter for patients in the AP group compared with the SS group (14.3 ± 5.9 d vs 18.7 ± 11.7 d, respectively, P = 0.049). The impact on hospital costs is one of the most frequently discussed consequences of SSI within a clinical setting. A few studies have presented data on the incidence and costs of infection for the hospital and post-discharge periods. As there were no incidences of post-discharge SSI in the current study, the costs-of-illness during hospitalization were incorporated into the overall costs. Total hospital costs were significantly lower for patients in the AP group than in the SS group (16407 ± 5284 $ vs 21879 ± 15784 $, respectively, P = 0.047). There is evidence suggesting that SSI prolongs the length of hospitalization for patients undergoing cardiac surgery, caesarean section, orthopedic surgery and general surgery, and increases the total costs of a patient’s treatment[28]. These results support the notion that intensive insulin therapy using a closed-loop glycemic control system after hepatic resection results in the maintenance of near normoglycemia, contributing to a reduction in both the incidence of SSI and total hospital costs per patient due to a decreased duration of hospitalization. Thus, the closed-loop system promises more effective and safer intensive insulin therapy in hepatectomized patients. An important question that has arisen from this study is how to choose candidates for intensive insulin therapy using a closed-loop system. This important issue must be addressed in future studies.
and,
Pseudomonas

However, a large international randomized trial in 2009 showed that a blood glucose target of less than 180 mg/dL resulted in lower mortality than a target of 81-108 mg/dL. Furthermore, contrary to this report, a recent meta-analysis did not support the benefits of intensive insulin therapy that it was not associated with significantly reduced hospital mortality but was associated with an increased risk of hypoglycemia. These randomized trials had several issues as follows: (1) trials were not blinded, (2) unusually high mortality in the usual care group, (3) parenteral nutrition (different administration of energy at the ICU), and (4) a markedly increased risk of hypoglycemia. To address this issue on the focus of a more effective blood glucose control method under impartial conditions without hypoglycemia, we are constructing a prospective randomized comparison study between intensive insulin therapy and moderate intensive insulin therapy using a closed-loop artificial endocrine pancreas. There were no occurrences of hypoglycemia during intensive insulin therapy using a closed-loop glycemic control system in our series of studies. In our experience of more than 200 patients in the surgical and medical ICU, we have not seen hypoglycemia develop in any patient when intensive insulin therapy is administered using a closed-loop glycemic control system (data not shown).

Enteral feeding was started as soon as possible after patients were hemodynamically stable. However, if the energy intake target could not be achieved, parenteral feeding was initiated to compensate for the deficit. In our series, all patients were given parenteral nutrition following surgery, with the total caloric requirement calculated according to the Harris-Benedict equation. Based on the results of our studies, maintaining an adequate calorie level, and controlling postoperative glucose levels with insulin therapy contributed to a reduction in the incidence of SSI. Moreover, the duration of hospitalization after liver surgery was reduced in patients who received perioperative tight glycemic control with intensive insulin therapy, and it is likely that this is related to a reduction in postoperative complications due to infection (SSI). In our studies, tight glycemic control was maintained for 18 h in patients in the surgical ICU after liver resection, and excellent glucose control was achieved without hypoglycemia using the closed-loop system.

Another outcome of our studies was that a brief period of glycemic control impacted on the incidence of SSI. Bacterial growth curves for Escherichia coli, Staphylococcus, Proteus, Staphylococcus and Pseudomonas, among others, indicate that under optimum conditions the greatest growth occurs between 2 and 18 h. We strongly believe that by instigating perioperative tight glycemic control for a brief period (at least 18 h) after surgery, postoperative infectious morbidity is decreased.

FUTURE DIRECTIONS

Clearly, we support a recent report that suggests that the development of accurate, continuous blood glucose

![Figure 2: Typical trend of blood glucose concentrations during the Pringle maneuver for hepatic resection (Maeda et al. Am J Surg 2009).](image)
monitoring devices (preferably closed-loop systems) for computer-assisted blood glucose control in the ICU will help prevent hypoglycemia[15]. However, using currently available technology, tight glucose control (i.e. targeting blood glucose levels of 80-110 mg/dL) using a closed-loop system in the surgical ICU was not achieved in 100% of cases, with the reported range being 60%-100%. Thus, further studies are needed to determine a better algorithm with which more accurate tight glucose control can be achieved. Regardless, we believe that by using the closed-loop glycemic control system during intensive insulin therapy in the ICU, the incidence of hypoglycemia and/or problems of nutritional support are reduced, as is the burden on nursing staff that is normally associated with the requisite frequent monitoring of blood glucose levels.

CONCLUSION

Intensive insulin therapy using a closed-loop artificial endocrine pancreas system during hepatic resection not only maintained near normoglycemia, but also contributed to a reduction in the rate of SSI and a decrease in total hospital costs due to shortened hospitalization. The closed-loop glycemic control system promises to revolutionize intensive insulin therapy for patients with disturbed glucose metabolism after liver resection.

REFERENCES

1 Ishida T, Lewis RM, Hartley CJ, Entman ML, Field JB. Comparison of hepatic extraction of insulin and glucagon in conscious and anesthetized dogs. Endocrinology 1983; 112: 1098-1109
2 Pringle JH. V. Notes on the Arrest of Hepatic Hemorrhage Due to Trauma. Ann Surg 1908; 48: 541-549
3 Cely CM, Arora P, Quartin AA, Kett DH, Schein RM. Relationship of baseline glucose homeostasis to hyperglycemia during medical critical illness. Chest 2004; 126: 879-887
4 McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001; 17: 107-124
5 Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death from myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355: 773-778
6 Huo TI, Lui WY, Huang YH, Chau GY, Wu JC, Lee PC, Chang FY, Lee SD. Diabetes mellitus is a risk factor for hepatic decompensation in patients with hepatocellular carcinoma undergoing resection: a longitudinal study. Am J Gastroenterol 2003; 98: 2293-2298
7 Little SA, Jarnagin WR, DeMatteo RP, Blumgart LH, Fong Y. Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer. J Gastrointest Surg 2002; 6: 88-94
8 Van den Berge G. Insulin therapy in the intensive care unit should be targeted to maintain blood glucose between 4.4 mmol/l and 6.1 mmol/l. Diabetologia 2008; 51: 911-915
9 Van den Berge G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 2003; 31: 359-366
10 Van den Berge G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1399-1407
11 Vilar-Compte D, Alvarez de Iturbe I, Martin-Onraet A, Perez-Adamor M, Sanchez-Hernandez C, Volkow P. Hyperglycemia as a risk factor for surgical site infections in patients undergoing mastectomy. Ann Intern Med 2008; 36: 192-198
12 Guvener M, Pasaoglu I, Demircin M, Oc M. Perioperative hyperglycemia is a strong correlate of postoperative infection in type II diabetic patients after coronary artery bypass grafting. Endocr J 2002; 49: 531-537
13 Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Rothermel M, Weiler N, Moerer O, Grond M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welle T, Schaefer M, Kern P, Kuhnt E, Kiehnottf M, Hartog C, Natanson C, Loefleff M, Reinhart K. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-139
14 Glucose control study: comparing the effects of two glucose control regimens by insulin in intensive care unit patients. Available from: URL: http://www.clinicaltrials.gov/ct/show/NCT00107601
15 Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 2008; 300: 933-944
16 Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hebert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297
17 Van den Berge G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijnjaarden E, Bobbaers H, Bouillon R. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449-461
18 Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA 2003; 290: 2041-2047
19 Toft P, Jørgensen HS, Toennes M, Christensen C. Intensive insulin therapy during general anesthesia for non-cardiac ICU patients: a prospective study. Acta Anaesthesiol Scand 2001; 45: 705-709
20 Alfonso A, Koops MK, Sung DP, Vigersky RA. Glycemic control with regular versus lispro insulin sliding scales in hospitalized Type 2 diabetics. J Diabetes Complications 2006; 20: 153-157
21 Dickerson LM, Ye X, Sack JL, Hueston WJ. Glycemic control in medical inpatients with type 2 diabetes mellitus receiving sliding scale insulin regimens versus routine diabetes medications: a multicenter randomized controlled trial. Ann Fam Med 2003; 1: 29-35
22 Yamashita K, Okabayashi T, Yokoyama T, Yatabe T, Maeda H, Manabe M, Hanazaki K. The accuracy of a continuous blood glucose monitor during surgery. Anesth Analg 2008; 106: 160-163, table of contents
23 Yamashita K, Okabayashi T, Yokoyama T, Yatabe T, Maeda H, Manabe M, Hanazaki K. Accuracy and reliability of continuous blood glucose monitor in post-surgical patients. Acta Anaesthesiol Scand 2009; 53: 66-71
24 Hanazaki K, Nose Y, Brunicardi FC. Artificial endocrine pancreas. J Am Coll Surg 2001; 193: 310-322
25 Okabayashi T, Hozaki K, Nishimori I, Sugimoto T, Yatabe T, Hozaki K, Danakana K, Kobayashi M, Yamashita K. Continuous post-operative blood glucose monitoring and control using a closed-loop system in patients undergoing hepatic resection. Dig Dis Sci 2008; 53: 1405-1410
26 Okabayashi T, Nishimori I, Yamashita K, Sugimoto T, Yatabe T, Maeda H, Kobayashi M, Hanazaki K. Risk factors and predictors for surgical site infection after hepatic
Okabayashi T et al. Insulin therapy after hepatic resection 4121

resection. *J Hosp Infect* 2009; **73**: 47-53

27 Okabayashi T, Nishimori I, Maeda H, Yamashita K, Yatabe T, Hanazaki K. Effect of intensive insulin therapy using a closed-loop glycemic control system in hepatic resection patients: a prospective randomized clinical trial. *Diabetes Care* 2009; **32**: 1425-1427

28 Alfonso JL, Pereperez SB, Canoves JM, Martinez MM, Martinez IM, Martin-Moreno JM. Are we really seeing the total costs of surgical site infections? A Spanish study. *Wound Repair Regen* 2007; **15**: 474-481

29 Figueras J, Llado L, Ruiz D, Ramos E, Busquets J, Rafecas A, Torras J, Fabregat J. Complete versus selective portal triad clamping for minor liver resections: a prospective randomized trial. *Ann Surg* 2005; **241**: 582-590

30 Ishizaki Y, Yoshimoto J, Miwa K, Sugo H, Kawasaki S. Safety of prolonged intermittent pringle maneuver during hepatic resection. *Arch Surg* 2006; **141**: 649-653; discussion 654

31 Belghiti J, Noun R, Malafosse R, Jagot P, Sauvanet A, Pierangeli F, Marty J, Farges O. Continuous versus intermittent portal triad clamping for liver resection: a controlled study. *Ann Surg* 1999; **229**: 369-375

32 Maeda H, Okabayashi T, Nishimori I, Yamashita K, Sugimoto T, Hanazaki K. Hyperglycemia during hepatic resection: continuous monitoring of blood glucose concentration. *Am J Surg* 2009; In press

33 Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. *N Engl J Med* 1994; **331**: 1547-1552

34 Harris JA, Benedict FG. A Biometric Study of Human Basal Metabolism. *Proc Natl Acad Sci USA* 1918; **4**: 370-373

35 Bowman RL, Blume P, Vurek GG. Capillary-tube scanner for mechanized microbiology. A photoelectric scanner measures growth in agar-filled capillaries and gives a new approach to microbiology. *Science* 1967; **158**: 78-83

S- Editor Tian L  I- Editor Webster JR  E- Editor Zheng XM